Trial results describe what happens under close supervision with motivated volunteers. A study published in August in The Lancet Diabetes & Endocrinology asked a harder question: among 45,093 real patients with obesity and type 2 diabetes, how many actually hit a meaningful combined target a year after starting treatment? The answer for semaglutide was 3.0%. … Read more
Eli Lilly announced on 26 August 2026 that a real-world analysis of adults over 55 found lower healthcare costs among people who stayed on Zepbound (tirzepatide) than among matched untreated adults, and framed the result against the $195 monthly net price under Medicare’s GLP-1 Bridge programme. The underlying paper is peer-reviewed and published in Diabetes, … Read more
The standard maintenance dose of Wegovy is 2.4 mg a week. STEP UP, a phase 3b randomised trial published in The Lancet Diabetes & Endocrinology, tested three times that — 7.2 mg — against both the standard dose and placebo over 72 weeks. Average weight loss was 20.7% on the high dose, 17.5% on 2.4 … Read more
The question people ask most often about these two drugs — which one works better — has a direct answer, and has had one since July 2025. In SURMOUNT-5, a trial that gave 751 adults either tirzepatide or semaglutide and followed them for 72 weeks, tirzepatide produced an average weight reduction of 20.2% against semaglutide’s … Read more
Novo Nordisk announced in February that from 1 January 2027 it will cut the US list price of Wegovy, Ozempic and Rybelsus to $675 a month — a reduction of roughly 50% for Wegovy and 35% for Ozempic. It is a genuinely large number and it made a lot of headlines. For most people reading … Read more